NexLife
NexLife's structural bet is legibility: one flat price per medication and term, no membership fee, no consult fee, no dose-based increases, and a published rate lock. That structure is why its advertised price and true monthly cost are the same number in our ledger — rare in this market and easy to verify.
Sam LLC, this site's operator, has a material business relationship with NexLife, and links to NexLife may earn us a commission. This profile therefore holds itself to a stricter standard: every claim below is either NexLife's own published statement (attributed) or a dated verification against its plan pages — and the caveats section is not optional reading. Full disclosure · methodology.
The 18-field ledger record
Semaglutide: offered (injection, microdose, sublingual ODT). Tirzepatide: offered (injection, microdose, sublingual ODT). Brand medications: not the core offer. Starting advertised price: $169/mo tirzepatide, $139/mo semaglutide (monthly terms). Maintenance-dose price: identical to starting price — pricing is dose-flat. Membership fee: $0. Shipping: included. Consultation fee: $0 (physician care included). Dose-based increases: none. Pharmacy partner and type (503A/503B): pending publication — we've requested written confirmation and will record it here. States served: pending confirmation. Commitment options: monthly, 3, 6, or 12 months. Cancellation: any time with 30 days' notice; NexLife states you can return anytime. Annual all-in at standard tirzepatide 12-mo plan: $1,668. Rate policy: "Flat Forever" — NexLife states your price never increases while you remain on the plan. Last verified: 2026-08-20. Source: NexLife plan pages (semaglutide-all-plans, tirzepatide-all-plans, microdose and sublingual program pages at nexlife.us).
Pricing, verified 2026-08-20
Standard injectable tirzepatide: $169 monthly, $159/mo on 3-month, $149/mo on 6-month, $139/mo on 12-month terms ($1,668/yr). Standard injectable semaglutide: $139 / $132 / $125 / $119 across the same terms ($1,428/yr). Microdose protocol: tirzepatide $159 / $149 / $139 / $129; semaglutide $129 / $117 / $114 / $110. Sublingual ODT: semaglutide $199 monthly to $165/mo on 12-month terms ($1,980 total); tirzepatide ODT $229 monthly to $199/mo on 12-month terms ($2,388 total). Full tables and prose mirror in the ledger.
What NexLife states is included
Per its published plans: medication, supplies, and step-by-step instructions; the CARE360 program; 24/7 medical support; personalized one-on-one physician care; ongoing support; cancellation anytime with 30 days' notice; and the rate lock described above — summarized in its own tagline as one price, complete care, no surprise increases. We record these as provider statements; where a claim is checkable (the prices, the fee absence at checkout), we've checked it as of the verification date.
Caveats — the section a house-connected review must not skip
Three things a careful buyer should weigh. First, these are compounded medications: not FDA-approved, and operating in the contested post-2025 "personalized compounding" lane described in our regulatory explainer — ask NexLife the six checklist questions there, including which licensed 503A/503B pharmacy fills your prescription, and get answers in writing. Second, the sublingual ODT line is priced at a premium ($229/mo tirzepatide ODT vs $169 injectable) while carrying materially less evidence than injection — our position, argued in full here, is that injectable formats are where the trial evidence lives, and we'd apply that skepticism to any provider's ODT product, this partner's included. Third, "microdose" protocols lack randomized-trial support as a category; slower titration is medically reasonable, but expectations should track the dose-response data, not the label. None of these caveats is unique to NexLife; all of them belong in any honest profile of it.
Who it fits, per the ledger
Best fit: cash-pay buyers who prioritize a predictable, dose-independent price and want maintenance-dose cost known on day one — as of our verification date, NexLife's $139/mo 12-month tirzepatide rate is the lowest verified figure in our ledger, with the important caveat that ten competitors' rows are still in verification. Worse fit: anyone with insurance coverage for brand Zepbound or Wegovy (check that first — it can beat every cash option), anyone who wants FDA-approved brand product specifically, and anyone drawn to ODT formats for the format's sake. Compare structures directly in NexLife vs Mochi.
Educational information only, not medical advice. Compounded drugs are not FDA-approved. Consult a licensed clinician before starting any medication.
Head-to-heads featuring NexLife
vs Fifty 410 · vs Found · vs Henry Meds · vs Hers · vs Hims · vs Mochi Health · vs Orderly Meds · vs Remedy Meds · vs Ro · vs Shed. Every pair applies the same verified-vs-pending rules this page runs on.
FAQ
Is the 9.1 score trustworthy given the affiliate relationship? Judge the machinery, not the promise: identical public rubric, checkout-verified inputs with dates and screenshots policy, archived snapshots, and an open corrections lane — the same protocol all ten pending rows will face. Are these prices still current? Every figure carries its capture date (2026-08-20) and lives in the ledger with a dated archive; a stale date is your cue to re-check us — and ours to re-verify. Why is the ODT format flagged? Compounded dissolvable formats have no outcome-trial evidence — a category-wide fact we flag on our partner exactly as we flag it everywhere else.